You are viewing a javascript disabled version of the site. Please enable Javascript for this site to function properly.
Go to headerGo to navigationGo to searchGo to contentsGo to footer
In content section. Select this link to jump to navigation

Author Index Volume 27 (2015)

The issue number is given in front of the page numbers

Acheampong, F., E. Bruce and B.P. Anto, Medication safety activities of hospital pharmacists in Ghana; challenges and perceived impact on patient care (1) 1–10

Adeoti, A.O., see Fadare, J.O. (4) 177–189

Agboola, S.M., see Fadare, J.O. (4) 177–189

Aina, F.O., see Fadare, J.O. (4) 177–189

Anantachoti, P., see Kaewpanukrungsi, W. (4) 225–237

Anto, B.P., see Acheampong, F. (1) 1–10

Antonuccio, D.O., see Högberg, G. (2) 85–91

Attard-Montalto, S., see Ellul, I.C. (3) 123–134

Bahl, A., see Kannan, S. (4) 219–223

Banerjee, M., see Bhowmick, S. (2) 101–102

Barati, O., see Khammarni, M. (4) 169–175

Barrett, C., see Darbyshire, D. (1) 23–33

Bavdekar, S.B., see Jobanputra, N. (3) 113–121

Bhardwaj, A., see Kannan, S. (2) 77–83

Bhowmick, S., P. Pal, B. Chakraborty, S. Sikdar, S. Chakraborty, M. Banerjee and A. Kundu, Letter to the Editor (2) 101–102

Boleat, E., see Griffiths, S.E. (4) 201–207

Bruce, E., see Acheampong, F. (1) 1–10

Bugden, S., see Hamilton, K. (4) 191–199

Card, A.J., see Simsekler, M.C.E. (2) 67–76

Chakraborty, B., see Bhowmick, S. (2) 101–102

Chakraborty, S., see Bhowmick, S. (2) 101–102

Clarkson, P.J., see Simsekler, M.C.E. (2) 67–76

D’Cruz, S., see Kashyap, M. (4) 209–217

Darbyshire, D., C. Barrett, D. Ross and D. Shackley, Measuring ward round quality in urology (1) 23–33

Davis, C., see Hamilton, K. (4) 191–199

Desalu, O.O., see Fadare, J.O. (4) 177–189

Drumond, N., see Gromek, K. (2) 55–65

Ellul, I.C., V. Grech and S. Attard-Montalto, Paediatric off-label and unlicensed prescribing in primary care in Malta: Prospective observational drug utilisation study (3) 123–134

Fadare, J.O., O.O. Desalu, A.M. Obimakinde, A.O. Adeoti, S.M. Agboola and F.O. Aina, Prevalence of inappropriate medication prescription in the elderly in Nigeria: A comparison of Beers and STOPP criteria (4) 177–189

Falk, J., see Hamilton, K. (4) 191–199

Gangadhar, B.N., see Rao, M.G. (3) 153–157

Goodwin, A., see Griffiths, S.E. (4) 201–207

Goonasekera, C., see Griffiths, S.E. (4) 201–207

Gowri, S., see Kannan, S. (2) 77–83

Grech, V., Atomic bomb testing and its effects on global male to female ratios at birth (1) 35–44

Grech, V., Response to a Letter to the Editor (2) 111–112

Grech, V., see Ellul, I.C. (3) 123–134

Griffiths, S.E., E. Boleat, A. Goodwin, A. Sheikh and C. Goonasekera, Efficacy of paediatric anaesthetic trolleys: A call for a basic standard and layout (4) 201–207

Gromek, K., N. Drumond and P. Simas, Pharmacovigilance of herbal medicines (2) 55–65

Hamilton, K., C. Davis, J. Falk, A. Singer and S. Bugden, High risk use of OTC NSAIDs and ASA in family medicine: A retrospective chart review (4) 191–199

Healy, D., see Högberg, G. (2) 85–91

Högberg, G., D.O. Antonuccio and D. Healy, Suicidal risk from TADS study was higher than it first appeared (2) 85–91

Jain, R., see Kannan, S. (2) 77–83

Jobanputra, N., S.U. Save and S.B. Bavdekar, Off-label and unlicensed drug use in children admitted to Pediatric Intensive Care Units (PICU) (3) 113–121

Kaewpanukrungsi, W. and P. Anantachoti, Performance assessment of the Thai National Center for Pharmacovigilance (4) 225–237

Kannan, S., A. Bahl and P.P. Khosla, Knowledge and perception of off-label drug use amongst prescribing physicians in a tertiary care hospital (4) 219–223

Kannan, S., S. Gowri, V. Tyagi, S. Kohli, R. Jain, P. Kapil and A. Bhardwaj, Direct-to-physician and direct-to-consumer advertising: Time to have stringent regulations (2) 77–83

Kapil, P., see Kannan, S. (2) 77–83

Kashyap, M., S. D’Cruz, A. Sachdev and P. Tiwari, Evidence-based information leads to reduction in inappropriate drug prescribing: Results from Indian older inpatients (4) 209–217

Keshtkaran, A., see Khammarni, M. (4) 169–175

Khammarni, M., R. Sharifian, A. Keshtkaran, F. Zand, O. Barati, E. Khonia and F. Setoodehzadeh, Prescribing errors in two ICU wards in a large teaching hospital in Iran (4) 169–175

Khonia, E., see Khammarni, M. (4) 169–175

Khosla, P.P., see Kannan, S. (4) 219–223

Kohli, S., see Kannan, S. (2) 77–83

Körblein, A., Concerning a Letter to the Editor (2) 103–105

Kundu, A., see Bhowmick, S. (2) 101–102

Kurutkan, M.N., E. Usta, F. Orhan and M.C.E. Simsekler, Application of the IHI Global Trigger Tool in measuring the adverse event rate in a Turkish healthcare setting (1) 11–21

Lalwani, T., see Saiyed, M.M. (1) 45–53

Lexchin, J., Formulary status of drugs in Ontario after Health Canada has issued a serious safety warning: A cohort study (3) 135–142

Obimakinde, A.M., see Fadare, J.O. (4) 177–189

Orhan, F., see Kurutkan, M.N. (1) 11–21

Pal, P., see Bhowmick, S. (2) 101–102

Rana, D., see Saiyed, M.M. (1) 45–53

Rao, M.G., S. Varambally, G. Venkatasubramanian and B.N. Gangadhar, Hazards of antihistamine dependence in psychiatric patients: A case report (3) 153–157

Ross, D., see Darbyshire, D. (1) 23–33

Sachdev, A., see Kashyap, M. (4) 209–217

Saiyed, M.M., T. Lalwani and D. Rana, Is off-label use a risk factor for adverse drug reactions in pediatric patients? A prospective study in an Indian tertiary care hospital (1) 45–53

Save, S.U., see Jobanputra, N. (3) 113–121

Scherb, H., Comment on a Letter to the Editor (2) 107–110

Setoodehzadeh, F., see Khammarni, M. (4) 169–175

Shackley, D., see Darbyshire, D. (1) 23–33

Sharifian, R., see Khammarni, M. (4) 169–175

Sheikh, A., see Griffiths, S.E. (4) 201–207

Sikdar, S., see Bhowmick, S. (2) 101–102

Simas, P., see Gromek, K. (2) 55–65

Simsekler, M.C.E., A.J. Card, J.R. Ward and P.J. Clarkson, Trust-level risk identification

guidance in the NHS East of England (2) 67–76

Simsekler, M.C.E., see Kurutkan, M.N. (1) 11–21

Singer, A., see Hamilton, K. (4) 191–199

Tiwari, P., see Kashyap, M. (4) 209–217

Tyagi, V., see Kannan, S. (2) 77–83

Urato, A.C., Are the SSRI antidepressants safe in pregnancy? Understanding the debate (2) 93–99

Usta, E., see Kurutkan, M.N. (1) 11–21

Varambally, S., see Rao, M.G. (3) 153–157

Venkatasubramanian, G., see Rao, M.G. (3) 153–157

Ward, J.R., see Simsekler, M.C.E. (2) 67–76

Zand, F., see Khammarni, M. (4) 169–175